The targeted therapies are tailored to the patient based on the specific genetic background of the tumor (e.g., mutation or altered expression of EGFR, KRAS, BRAF, PIK3CA, PTEN, HER2, or gene fusion of ALK, ROS1, RET) [65]. This evidence concerns the gene PTEN and neoplasm.